- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Stomach cancer is an abnormal growth of malignant cells in the lining of the stomach. Stomach cancer, also known as gastric cancer, can affect any part of the stomach. In most countries of the world, stomach cancers form in the main part of the stomach (stomach body). The main risk factors are age, diet and pre-existing stomach disease.
Showing all 6 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
03/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
01/2019 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2020 |
182,70 € |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin